Wang W, Liu X, Hou X, et al. - Among patients with cervical squamous cell carcinoma (n = 559) who received concurrent chemoradiotherapy, researchers examined the link between posttreatment squamous cell carcinoma antigen (SCC Ag) and treatment failure. They evaluated the cutoff value of posttreatment SCC Ag in predicting treatment failure by using a receiver operating characteristic (ROC) curve. The optimal cutoff posttreatment SCC Ag level was identified to be 1.8 ng/mL, with the ROC curve, with a sensitivity and specificity of 27.1% and 96.6%, respectively. Multivariate analysis revealed posttreatment SCC Ag as an independent prognostic factor of disease-free survival (DFS). They noted that patients with posttreatment SCC Ag < 1.8 ng/mL and ≥ 1.8 ng/mL had 3-year overall survival, DFS, local control, and distant control rates of 90.7% and 46.4%, 84.8% and 31.9%, 81.4% and 69.5%, and 90.4% and 54.1%, respectively. A high rate of treatment failure and poor survival was observed in patients with posttreatment SCC Ag ≥ 1.8 ng/mL.